Deserves every penny of it--we (shareholders) are fortunate to have him leading the co.--Great CEO !!!! Would like to go to next yrs. Annual meeting to shake his hand to thank him and congratulate him !!!!
They must know something ! http://wwwDOTamericanbankingnewsDOTcom/2016/04/01/anavex-life-sciences-avxld-outperform-rating-reiterated-at-fbr-co/
go to this site and listen to Dr.Misslings presentation--takes a few minutes to hear the whole thing but well worth the time--simply amazing !!!! knock your socks off good !! http://wwwDOTanavexDOTcom/investors/investor-material/ replace the Dot with .
Just finished listening to the webcast myself--Mindboggleing good stuff--happy to own a bunch of shares--not selling anytime soon---great future here !!!!!!
Have to agree with you george---in the pipeline:Alzheimer's,MS,Parkinsen's,Depression,Anxiety,Epilepsy,Pancreatic Cancer,Prostate Cancer---the good Dr.and his team are working on the Silver Bullet !
All I can say is GADZOOKS--we're sitting on a GOLD MINE here !!!!!!! Hold tight !
video---longs do watch this---very informing----http://wwwDOTepilepsyDOTcom/accelerating-new-therapies/2016-epilepsy-pipeline-conference/session-ix-clinical-drugs#14 (replace the DOT with .)
Dr. Missling would be the person to comment on that--I have my faith in him and his management team---the real deal !!!
FBR Capital initiates coverage on Anavex Life Sciences (NASDAQ: AVXL) with a Outperform rating and a price target of $10.00.
Analyst Christopher James commented, "Anavex is developing a mixed muscarinic/sigma-1 (σ1) protein agonist, Anavex 2-73 (AV2-73), for the potential treatment of neurological diseases. We believe the broad applicability and therapeutic utility of a sigma-1 receptor modulator could have use in a number of additional neurological diseases, including multiple sclerosis (MS), depression, anxiety, and epilepsy. The company's lead program is investigating AV2-73 for the treatment of Alzheimer's disease, which is currently in Phase II development. In addition, Anavex recently announced preclinical data supporting AV2-73's use in a rare and debilitating disorder, Rett syndrome. Given Rett syndrome's orphan disease status, we believe an accelerated path to approval could position Rett syndrome to be AV2-73's first approved indication. In 2016, we expect additional readouts for the Phase IIa study in Alzheimer's disease (AD), initiation of a Phase II study in Rett syndrome, and potential updates on other preclinical programs."